Masitinib in Patients With Mild Alzheimer's Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Alzheimer Disease
Interventions
DRUG

Placebo

treatment per os

DRUG

Masitinib (4.5)

Masitinib (titration to 4.5 mg/kg/day)

DRUG

Standard of care

Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine

Trial Locations (9)

Unknown

Institut de la mémoire et Maladie d'Alzheimer, Hôpitaux Universitaires Pitié-Salpêtrière, Paris

Hospital Universitario Nuestra Señora del Perpetuo Socorro de Albacete (Hospital Universitario Nuestra Señora del Perpétuo Socorro), Albacete

Ace Alzheimer Center Barcelona (Fundació ACE), Barcelona

Hospital Policlínico de Gipuzkoa, Donostia / San Sebastian

Virgen de las Nieves University Hospital (Hospital Universitario Virgen de las Nieves), Granada

La Paz University Hospital (Hospital Universitario La Paz), Madrid

Hospital Clinico Universitario Virgen de la Arrixaca, Murcia

Hospital Universitario de Navarra, Pamplona

Complejo Asistencial de Zamora. Hospital Provincial de Zamora, Zamora

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AB Science

INDUSTRY